Anavex treasurer's four option awards vest

The four option lots have expiration dates ranging from June 27, 2032, to March 31, 2035.

Rhea-AI Filing Summary

ANAVEX LIFE SCIENCES CORP. reported that Sandra Boenisch, PFO & Treasurer, had four previously granted stock-option awards become immediately vested and exercisable on September 24, 2026. The options cover 20,000 shares at a $10.09 exercise price, 25,000 at $8.57, 25,000 at $5.36 and 25,000 at $8.58. The vesting followed the board election at the 2026 Annual Meeting, which the company described as a “change in control” under its incentive plans and her employment agreement.

Insider Trade Summary

Grant/Award: 95,000 shares

Grant/Award 4 txns

Insider Boenisch Sandra

Role PFO & Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	20,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1	25,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1	25,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 95,000 contracts (Direct)

Footnotes (1)

1. F1. As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.

Key Figures

Option award: 20,000 options Exercise price: $10.09 per share Option award: 25,000 options +5 more

8 metrics

Option award 20,000 options Granted June 27, 2022; expires June 27, 2032

Exercise price $10.09 per share Options granted June 27, 2022

Option award 25,000 options Granted March 31, 2023; expires March 31, 2033

Exercise price $8.57 per share Options granted March 31, 2023

Option award 25,000 options Granted February 20, 2024; expires February 20, 2034

Exercise price $5.36 per share Options granted February 20, 2024

Option award 25,000 options Granted March 31, 2025; expires March 31, 2035

Exercise price $8.58 per share Options granted March 31, 2025

Key Terms

change in control, performance-based vesting terms, vested and exercisable

3 terms

change in control technical

"election of the Issuer's board of directors ... constituted a "change in control""

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

performance-based vesting terms financial

"not been previously reported due to their performance-based vesting terms"

vested and exercisable financial

"all outstanding and unvested awards ... became immediately vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the grant dates and terms of Sandra Boenisch's AVXL options?

The reported option lots were: 20,000 options granted June 27, 2022, at $10.09 per share, expiring June 27, 2032; 25,000 granted March 31, 2023, at $8.57, expiring March 31, 2033; 25,000 granted February 20, 2024, at $5.36, expiring February 20, 2034; and 25,000 granted March 31, 2025, at $8.58, expiring March 31, 2035.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/28/2026 - 09:37 PM Accepted by SEC EDGAR 09/28/2026 - 09:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boenisch Sandra

(Last) (First) (Middle)

630 5TH AVENUE, 20TH FLOOR

(Street)

NEW YORK NEW YORK 10111

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PFO & Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.09	09/24/2026		A		20,000		09/24/2026	06/27/2032	Common Stock	20,000	$0	20,000(1)	D
Stock Option (Right to Buy)	$8.57	09/24/2026		A		25,000		09/24/2026	03/31/2033	Common Stock	25,000	$0	25,000(1)	D
Stock Option (Right to Buy)	$5.36	09/24/2026		A		25,000		09/24/2026	02/20/2034	Common Stock	25,000	$0	25,000(1)	D
Stock Option (Right to Buy)	$8.58	09/24/2026		A		25,000		09/24/2026	03/31/2035	Common Stock	25,000	$0	25,000(1)	D

Explanation of Responses:

1. As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.

	/s/ Sandra Boenisch	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)